SCHEMBL22480930

SCHEMBL22480930

BC(B)(B)C(NCC(O)c1cccnc1C)(C(B)(B)B)C(B)(B)B

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 4/20 0.39
ADRB2 P07550 3/20 0.39
HIF1A Q16665 2/20 0.39
CYP2D6 P10635 2/20 0.39
NFKB1 P19838 1/20 0.39
BLM P54132 1/20 0.38
CYP2C19 P33261 1/20 0.36
P2RX7 Q99572 1/20 0.35
RORC P51449 1/20 0.33
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
FDPS P14324 1/20 0.31
ADRA2A P08913 1/20 0.31
ADRB3 P13945 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
CTSA P10619 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22480735 0.84 HIF1A (0.56) ADRB1ADRB2HIF1ACYP2D6NFKB1
SCHEMBL22493460 0.84 HIF1A (0.56) ADRB1ADRB2HIF1ACYP2D6NFKB1
SCHEMBL22481180 0.84 HIF1A (0.56) ADRB1ADRB2HIF1ACYP2D6NFKB1
SCHEMBL28336015 0.73 LMNA (0.41) HIF1ACYP2C19P2RX7RORCTSHR
SCHEMBL17681956 0.73 LMNA (0.41) HIF1ACYP2C19P2RX7RORCTSHR
SCHEMBL17681986 0.73 LMNA (0.41) HIF1ACYP2C19P2RX7RORCTSHR
SCHEMBL29240503 0.72 P2RX7 (0.39) HIF1ACYP2C19P2RX7RORCTSHR
SCHEMBL30325110 0.72 P2RX7 (0.39) HIF1ACYP2C19P2RX7RORCTSHR
SCHEMBL29240506 0.72 P2RX7 (0.39) HIF1ACYP2C19P2RX7RORCTSHR
SCHEMBL30324716 0.72 P2RX7 (0.39) HIF1ACYP2C19P2RX7RORCTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-08-24 US disclosed
US-20230157974-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20220169612-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. 2022-06-02 US disclosed
US-20210371380-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. 2021-12-02 US disclosed
US-11040944-B2 Beta adrenergic agonist and methods of using the same CURASEN THERAPEUTICS, INC. (US) 2021-06-22 US disclosed
US-10947196-B2 Beta adrenergic agonist and methods of using the same CURASEN THERAPEUTICS, INC. (US) 2021-03-16 US disclosed
US-20200308115-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. 2020-10-01 US disclosed
US-20200308114-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. 2020-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200308114-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRB2, ADRB1, ADRA2C ADRB1 2/4885ADRB2 1/4885HIF1A 2371/4885
US-20200308115-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRB2, ADRB1, ADRA2C ADRB1 2/4885ADRB2 1/4885HIF1A 2371/4885
US-10947196-B2 Beta adrenergic agonist and methods of using the same ADRB2, ADRB1, ADRA2C ADRB1 2/4885ADRB2 1/4885HIF1A 2371/4885
US-20210371380-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRB2, ADRB1, ADRA2C ADRB1 2/4885ADRB2 1/4885HIF1A 2371/4885
US-11040944-B2 Beta adrenergic agonist and methods of using the same ADRB2, ADRB1, ADRA2C ADRB1 2/4885ADRB2 1/4885HIF1A 2371/4885
US-20220169612-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRA2B, ADRB2, ADRB1 ADRB1 3/4885ADRB2 2/4885HIF1A 3024/4885
US-20230263749-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A ADRB1 5/4885ADRB2 4/4885HIF1A 701/4885
US-20230157974-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS ADRA2A, SNCA, ADRA1A ADRB1 5/4885ADRB2 4/4885HIF1A 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.